Meg Tirrell joined CNBC in April 2014 as a general assignment reporter focusing on biotechnology and pharmaceuticals. She appears on CNBC's Business Day programming, contributes to CNBC.com and is based at the network's global headquarters in Englewood Cliffs, N.J.
Prior to joining CNBC, she led coverage of the biotechnology industry for Bloomberg News. She broke news on the proxy fights at Forest Labs and Vivus, the return of Ariad's cancer drug to market and the merger & acquisition story of Amylin Pharmaceuticals and Genzyme. She has written features that illuminate how science and business meet, and the effect on our health. She also contributed to Bloomberg Television and Bloomberg Businessweek.
She holds a master's degree in journalism from Northwestern University and a bachelor's degree in English and music from Wellesley College.
Follow her on Twitter @megtirrell.
Ilan Ganot left his banking job to form a company to develop drugs to treat his 4-year-old son, who has Duchenne muscular dystrophy.
Infinity Pharma will receive $275 million upfront from AbbVie, as part of a new venture to develop blood cancer treatments. Infinity CEO Adelene Q. Perkins, explains the significance of the deal, with CNBC's Meg Tirrell.